| Title |
Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin’s Lymphoma
|
|---|---|
| Published in |
Clinical Pharmacokinetics, September 2012
|
| DOI | 10.2165/11594410-000000000-00000 |
| Pubmed ID | |
| Authors |
Andrzej Hellmann, Simon Rule, Jan Walewski, Ofer Shpilberg, Huaibao Feng, Helgi van de Velde, Hamina Patel, Donna M. Skee, Suzette Girgis, Vernon J. Louw |
| Abstract |
Bortezomib, an antineoplastic agent with proteasome inhibitory activity, is extensively metabolized by the hepatic microsomal cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C19. Drugs that affect these enzymes may therefore have an impact on the pharmacological profile of bortezomib. This study evaluated the effects of co-administration of a potent CYP3A4 inducer (rifampicin [rifampin]) and a weak CYP3A4 inducer (dexamethasone) on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 24% |
| Student > Bachelor | 5 | 12% |
| Student > Doctoral Student | 4 | 10% |
| Other | 4 | 10% |
| Student > Ph. D. Student | 4 | 10% |
| Other | 9 | 22% |
| Unknown | 5 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 29% |
| Agricultural and Biological Sciences | 6 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 12% |
| Psychology | 5 | 12% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Other | 3 | 7% |
| Unknown | 8 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 November 2011.
All research outputs
#20,656,820
of 25,374,917 outputs
Outputs from Clinical Pharmacokinetics
#1,421
of 1,602 outputs
Outputs of similar age
#146,497
of 187,199 outputs
Outputs of similar age from Clinical Pharmacokinetics
#435
of 450 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,602 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 4th percentile – i.e., 4% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,199 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 450 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.